dbacp04503
General Description
Peptide name : Magainin A
Source/Organism : African clawed frog
Linear/Cyclic : Linear
Chirality : L
Sequence Information
Sequence : AIGKFLHSAKKFGKAFVGEIMNS
Peptide length: 23
C-terminal modification: Linear
N-terminal modification : Amidation
Non-natural peptide information: None
Activity Information
Assay type : MTT/MTS assay
Assay time : 24h
Activity : IC50 : 9.7 µM
Cell line : NCI-H841
Cancer type : Lung cancer
Other activity : Not found
Physicochemical Properties
Amino acid composition bar chart :
Molecular mass : 2480.9238 Dalton
Aliphatic index : 0.765
Instability index : 3.587
Hydrophobicity (GRAVY) : 0.1783
Isoelectric point : 10.001
Charge (pH 7) : 2.8819
Aromaticity : 0.130
Molar extinction coefficient (cysteine, cystine): (0, 0)
Hydrophobic/hydrophilic ratio : 1.55555555
hydrophobic moment : -0.028
Missing amino acid : C,R,W,Q,T,P,D,Y
Most occurring amino acid : K
Most occurring amino acid frequency : 4
Least occurring amino acid : L
Least occurring amino acid frequency : 1
Structural Information
3D structure :
Secondary structure fraction (Helix, Turn, Sheet): (0.4, 0.2, 0.3)
SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@H](C)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)CC)C(C)C
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | HHHHHHHHHHHHHHHHHHHHHHT |
| Chou-Fasman (CF) | CCHHHHHHHHHHHHEEECCCCCC |
| Neural Network (NN) | HHHHHHHHHCCCCCCHHHHHCCC |
| Joint/Consensus | HHHHHHHHHHHHHHCHHHHHCCC |
Molecular Descriptors and ADMET Properties
Molecular Descriptors: Click here to download
ADMET Properties: Click here to download
Cross Referencing databases
Reference
1 : Huang CM, et al. Magainin analogs effective against pathogenic protozoa. Antimicrob Agents Chemother. 1990; 34:1824-6. doi: 10.1128/AAC.34.9.1824
2 : Ohsaki Y, et al. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 1992; 52:3534-8.
Literature
Paper title : Magainin analogs effective against pathogenic protozoa.
Doi : https://doi.org/10.1128/AAC.34.9.1824
Abstract : The in vitro activities of magainin analogs against Blastocystis hominis, Entamoeba histolytica, and Trypanosoma cruzi were assessed by protozoan morphological integrity and motility. The antiprotozoan activities in descending order were magainin B greater than G greater than H, the same order as the alpha-helix contents of the analogs. Magainin B and G were effective against B. hominis, T. cruzi, and E. histolytica.
Paper title : Antitumor activity of magainin analogues against human lung cancer cell lines.
Doi : https://doi.org/Not available
Abstract : Magainin 1 and magainin 2, originally isolated from African clawed frog Xenopus laevis skin, inhibit the growth of bacteria and fungi. Synthetic magainin A (MAG A) and magainin G (MAG G) are more potent against bacteria and protozoa. In order to determine the antitumor activity of these analogues, we have tested these two analogues against six small cell lung cancer (SCLC) cell lines NCI-H82, NCI-H526, NCI-H678, NCI-H735, NCI-H841, and NCI-H889, which were known to differ by more than 10-fold in their sensitivity to different chemotherapeutic agents, and four normal human fibroblast cell lines. Semiautomated 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of the six SCLC cell lines revealed average concentrations producing 50% inhibition (IC50) values of 2.6 microM (range, 0.49-9.30 microM) for cisplatin, 2.5 microM (range, 0.39-6.00 microM) for etoposide, and 138.8 nM (range, 55.0-450.0 nM) for doxorubicin. The average IC50 of MAG A was 8.64 microM (range, 6.23-11.7 microM) and that of MAG G was 8.82 microM (range, 4.44-12.5 microM) against the SCLC cell lines. Despite a 10-fold difference in sensitivity to standard chemotherapeutic agents, the IC50 of MAG A and MAG G differs by less than 3-fold. The average IC50 against four normal human fibroblast cell lines was 21.1 microM (range, 12.7-25.6 microM) for MAG A and 29.2 microM (range, 21.3-34.8 microM) for MAG G. Combined exposure to the IC50 concentration of MAG A or MAG G plus IC50 of etoposide or cisplatin decreased the percentage of surviving SCLC cells to 29.0% (range, 26.1-31.7%). MAG A or MAG G had an additive effect when used with standard chemotherapeutic agents. These data suggest that MAG A and MAG G have in vitro antitumor activity against SCLC cell lines.